Inovio Pharmaceuticals' (INO +14.7%) vaccine for the newly emergent A/Anhui/1/13 subtype of the...

|About: Inovio Pharmaceuticals, Inc. (INO)|By:, SA News Editor

Inovio Pharmaceuticals' (INO +14.7%) vaccine for the newly emergent A/Anhui/1/13 subtype of the H7N9 strain of bird flu protected 100% of mice in a pre-clinical study, with all the animals surviving despite receiving a lethal dose of the virus. However, Inovio is behind Novavax (NVAX), which has already started Phase I trials for A/Anhui/1/13-like A(H7N9). (PR)